Navigation Links
Terminal in Medical Technology

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... exhibited significantly greater increase in mean terminal hair density than that seen in subjects treated ... that is healthy and capable of producing thick terminal hair. The enhanced environment in turn ... hair loss and stimulates the re-growth of thicker terminal hair. The HairMax LaserComb utilizes a ...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

... (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased ... on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in humans, ... Erythropoietin by Fusing the Carboxyl- terminal Peptide of Human Chorionic Gonadotropin b-Subunit ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

... (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. IST has genetically engineered an antibody drug that ... IST's CEO, Mr. Alan Liddle, said multiple myeloma is a very debilitating terminal disease, with an estimated patient population of over 100,000 worldwide. ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

... Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ... with Eculizumab in CAD A poster titled "Long-term Efficacy of the terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease" ...

Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP

... by researchers at Washington University in St. Louis and is based on a short amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide (CTP). When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the ...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... today at the 50th Annual Meeting of the American Society of Hematology in San Francisco in a poster session titled, "Safety and Efficacy of the terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results." The study was ...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

... wall of the intestine and in regional lymph nodes. After an incubation period of several years, extensive granulomatous inflammation occurs in the terminal small intestine, leading to malabsorption and protein-losing enteropathy. Cattle shed minimal amounts of M. paratuberculosis in their feces during ...

Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta

... Modigene's technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in humans and when attached to a therapeutic protein, extends the time that the protein is active in the body. ...

eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials

... and research on computer interviewing, described some of the benefits of SMS: "SMS provides a user-friendly telephone interface as a computer terminal to collect sensitive suicidality data directly from trial subjects. Advantages of Interactive Voice Response (IVR) technology are: constant ...

Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies

... of lupus-prone mice. The mice in the R788 groups orally received 10 mg/kg, 20 mg/kg or 40 mg/kg twice a day, for 240 days. Baseline, periodic and terminal measurements of renal enzymes and proteinuria (presence of proteins in the urine associated with kidney malfunctions), blood urea nitrogen, and other ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... dose could not be defined despite achieving high concentrations in blood. APD791 was rapidly absorbed and exposures were generally related to dose. terminal half-life (t1/2) of the parent plus active metabolites was also related to dose, and was approximately 11 hours at the higher doses. Dose dependent ...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

... increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-beta-hydroxylase enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-alpha-demethylase, a ...

FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function

... be significant in the treatment of cardiovascular disease." Adult heart muscle cells lack the ability to regenerate following injury because of terminal differentiation. The number of heart cells is determined at birth and once damaged cannot repair themselves. Furthermore, many congenital ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

... and their bacterial loads determined by plating bone homogenates. The pharmacokinetic study of TT99000647 revealed a Cmax at 303 mcg/g of bone and a terminal half-life of 131 hours in bone. In the efficacy study, treatments resulted in the following proportion of sterilized tibia: 14% (untreated controls); ...

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

... or decreased during RDEA806 dosing. The systemic exposure of RDEA806 increased linearly from 50 mg to 600 mg under fasted or fed conditions. The terminal half-life of RDEA806 was up to 11 hours after single doses and up to 13 hours following multiple doses. With doses of 300 mg to 500 mg twice daily, ...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

... in Vienna. These presentations included: "The terminal Complement Inhibitor Eculizumab Reduces ... (Abstract No. 0380) "Safety and Efficacy of the terminal Complement Inhibitor Eculizumab in Patients with ... when a duty arises under law. 1 Hillmen P. The terminal Complement Inhibitor Eculizumab Reduces ...

Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150

... AEOL 10150 2 mg/kg/day resulted in lower, but sustained, plasma levels of approximately 1,500 ng/ml. Steady state occurred within three days and the terminal half-life was approximately 8 to 9 hours. Fifty-five percent of the dose was excreted in the urine as unchanged AEOL 10150. The maximum tolerated ...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

... 4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after administration -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours) -- The bioavailability of single doses of i.m. peramivir is high (>98%) -- Peramivir was well-tolerated in ...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

... technology was discovered by researchers at Washington University in St. Louis, Missouri, and is based on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in the human body, and when attached to a therapeutic protein, extends the time that such protein can ...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

... 2 diabetes. It is a single enantiomer of racemic ketoconazole which suppresses cortisol production by inhibiting the 11 beta hydroxylase enzyme, the terminal step in the adrenal synthesis of cortisol. This novel mechanism of action makes DIO-902 a first-in-category cortisol inhibitor. "Our unique ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Elimination ...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Elimination ...
Other Contents
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
(Date:7/10/2014)... Intelligence today released forecasts from "The Global National eID ... for National Electronic ID (eID) programs will generate $54 billion ... number of National eID cards in circulation will double from ... with its vast population, will dominate the market representing nearly ... Europe trails a distant second at 11%. ...
Breaking Biology News(10 mins):Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... July 12, 2014 Doylestown Hospital recently ... variety of men’s health questions. Paddock tackles topics ... men, why women live longer than men, and testosterone ... Health Made Simple featured on Doylestown Hospital’s website, ... hernia at any age. If you notice pain, bulging, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Utah Valley ... of startups, with awards being bestowed to companies in ... Utah’s outstanding entrepreneur community with recognition for new ideas ... model with incoming revenue. , 25 Under 5 highlights ... state that are under 5 years old. Award recipients ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
Other TagsOther Tags